paclitaxel has been researched along with pteridines in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dunn, SE; Fotovati, A; Hu, K; Law, JH | 1 |
| Albitar, L; Brachova, P; Dai, D; Ianzini, F; Kosmacek, EA; Laidler, LL; Leslie, KK; Liu, D; Mackey, MA; Meng, X; Wang, X; Xiong, Z; Yang, S; Zhang, Y; Zhu, D | 1 |
| Benes, C; Florian, S; Mitchison, TJ; Moerke, N; Shamu, C; Tang, Y; Xie, T | 1 |
| Biankin, AV; Caldon, CE; Clark, SJ; Cowley, MJ; Gallego-Ortega, D; Gee, JM; McCloy, RA; Musgrove, EA; Nicholson, RI; Ormandy, CJ; Print, CG; Sergio, CM; Stone, A; Valdes-Mora, F | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Bharti, R; Mandal, M; Parida, S; Prashanth Kumar, BN; Rajput, S | 1 |
| Jemaà, M; Kifagi, C; Massoumi, R; Serrano, SS | 1 |
| Jang, HR; Kim, CH; Shin, SB; Yim, H | 1 |
8 other study(ies) available for paclitaxel and pteridines
| Article | Year |
|---|---|
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Doxorubicin; Female; Fluorouracil; Gene Expression; Gene Knockdown Techniques; Gene Library; Humans; Hyaluronan Receptors; Molecular Targeted Therapy; Neoplastic Stem Cells; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA Interference; RNA, Small Interfering | 2012 |
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Mitosis; Paclitaxel; Pteridines; Quinazolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay.
Topics: Antimitotic Agents; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Fluorescent Dyes; Heterocyclic Compounds, 2-Ring; High-Throughput Screening Assays; Humans; Molecular Imaging; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Topics: Antimitotic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biomarkers; Biphenyl Compounds; Breast Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Heterocyclic Compounds, 2-Ring; Humans; MCF-7 Cells; Neoplasm Metastasis; Nitrophenols; Nocodazole; Paclitaxel; Piperazines; Prognosis; Pteridines; Sulfonamides | 2013 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cellular Senescence; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; In Situ Nick-End Labeling; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Pteridines; Signal Transduction; Tamoxifen; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Topics: Antimitotic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Colchicine; Colonic Neoplasms; Drug Synergism; Humans; Microtubules; Mitochondria; Mitosis; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; RNA, Small Interfering; Tetraploidy; Tubulin Modulators; Vincristine | 2020 |
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
Topics: A549 Cells; Cell Cycle Proteins; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes; Ubiquitin-Specific Peptidase 7 | 2020 |